MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed...

Area of Science:

• Molecular Biology
• Cancer Genomics
• Epigenetics

Background:

• Promoter hypermethylation is a key mechanism in cancer development, leading to the silencing of critical genes.
• Quantitative methylation analysis (MA) is crucial for cancer research and diagnostics.
• Existing MA methods often require bisulfite treatment or fluorescent probes, posing limitations.

Purpose of the Study:

• To introduce MethyQESD (methylation-quantification of endonuclease-resistant DNA) as a novel, efficient method for quantitative MA.
• To establish and validate MethyQESD for MLH1 promoter methylation analysis.
• To assess MethyQESD's utility in distinguishing hereditary nonpolyposis colorectal cancer (HNPCC) from sporadic microsatellite-unstable (MSI-H) colorectal cancer (CRC).

Main Methods:

• Developed and applied MethyQESD for quantitative MLH1 promoter methylation analysis.
• Utilized formalin-fixed and paraffin-embedded (FFPE) colorectal cancer tissue samples.
• Validated MethyQESD accuracy through spiking experiments and compared it with conventional MA methods.

Main Results:

• MethyQESD demonstrated high accuracy in spiking experiments (Pearson's r > 0.997).
• MethyQESD showed strong concordance with conventional MA (Pearson's r = 0.885).
• HNPCC tumors exhibited significantly lower MLH1 methylation compared to sporadic MSI-H CRC (P<0.001); MSS tumors showed no MLH1 methylation.
• A cutoff of 16.5% MLH1 methylation accurately identified sporadic MSI-H CRC (AUC = 1.000, P<0.001).

Conclusions:

• Quantitative MLH1 MA using MethyQESD is a simple, fast, and valuable tool for identifying HNPCC candidates.
• MethyQESD is reliable for FFPE tissues, simplifying DNA MA for research and diagnostics.
• This method enhances the diagnostic capabilities for differentiating colorectal cancer subtypes.